ABL1 is altered in 3.47% of myeloproliferative neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 9 clinical trials for myeloproliferative neoplasm, of which 5 are open and 4 are closed. Of the trials that contain ABL1 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 9 clinical trials for myeloproliferative neoplasm, of which 4 are open and 5 are closed. Of the trials that contain AFF1 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

ASXL1 is altered in 16.17% of myeloproliferative neoplasm patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is altered in 4.07% of myeloproliferative neoplasm patients [2].

BCR is an inclusion eligibility criterion in 9 clinical trials for myeloproliferative neoplasm, of which 5 are open and 4 are closed. Of the trials that contain BCR status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

CBFB is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 2 are open and 2 are closed. Of the trials that contain CBFB status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

DEK is an inclusion eligibility criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain DEK status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

ELL is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain ELL status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

FGF1 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF10 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF14 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF23 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF3 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF4 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF5 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF6 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 0.2% of myeloproliferative neoplasm patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is altered in 0.2% of myeloproliferative neoplasm patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FLT3 is altered in 3.37% of myeloproliferative neoplasm patients [2].

FLT3 is an inclusion eligibility criterion in 10 clinical trials for myeloproliferative neoplasm, of which 6 are open and 4 are closed. Of the trials that contain FLT3 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

IDH1 is altered in 1.38% of myeloproliferative neoplasm patients [2].

IDH1 is an inclusion eligibility criterion in 3 clinical trials for myeloproliferative neoplasm, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

IDH2 is altered in 1.49% of myeloproliferative neoplasm patients [2].

IDH2 is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 4 are open and 0 are closed. Of the trials that contain IDH2 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IGH status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

IKZF1 is altered in 0.26% of myeloproliferative neoplasm patients [2].

IKZF1 is an inclusion eligibility criterion in 2 clinical trials for myeloproliferative neoplasm, of which 1 is open and 1 is closed. Of the trials that contain IKZF1 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

KIT is altered in 0.59% of myeloproliferative neoplasm patients [2].

KIT is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain KIT status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

KMT2A is altered in 0.91% of myeloproliferative neoplasm patients [2].

KMT2A is an inclusion eligibility criterion in 11 clinical trials for myeloproliferative neoplasm, of which 5 are open and 6 are closed. Of the trials that contain KMT2A status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAF status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 11 clinical trials for myeloproliferative neoplasm, of which 7 are open and 4 are closed. Of the trials that contain MECOM status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain MLF1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain MLLT1 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain MLLT10 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain MLLT3 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain MLLT4 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MYH11 is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 2 are open and 2 are closed. Of the trials that contain MYH11 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

NPM1 is altered in 1.49% of myeloproliferative neoplasm patients [2].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain NRIP3 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

NUP214 is an inclusion eligibility criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain NUP214 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

PBX1 is an inclusion eligibility criterion in 5 clinical trials for myeloproliferative neoplasm, of which 3 are open and 2 are closed. Of the trials that contain PBX1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

PML is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PML status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

RARA is an inclusion eligibility criterion in 1 clinical trial for myeloproliferative neoplasm, of which 0 are open and 1 is closed. Of the trial that contains RARA status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 11 clinical trials for myeloproliferative neoplasm, of which 7 are open and 4 are closed. Of the trials that contain RPN1 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [3].

RUNX1 is altered in 3.09% of myeloproliferative neoplasm patients [2].

RUNX1 is an inclusion eligibility criterion in 5 clinical trials for myeloproliferative neoplasm, of which 3 are open and 2 are closed. Of the trials that contain RUNX1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 4 clinical trials for myeloproliferative neoplasm, of which 2 are open and 2 are closed. Of the trials that contain RUNX1T1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

TCF3 is an inclusion eligibility criterion in 5 clinical trials for myeloproliferative neoplasm, of which 3 are open and 2 are closed. Of the trials that contain TCF3 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

TP53 is altered in 3.96% of myeloproliferative neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain TP53 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].